Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leah J Anderson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of General Virology|June 19, 2008
EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathwayLeah J Anderson, Richard Longnecker
Blood|September 26, 2008
Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivoLeah J Anderson, Richard Longnecker
Virology|November 6, 2007
An auto-regulatory loop for EBV LMP2A involves activation of NotchLeah J Anderson, Richard Longnecker
Virology Journal|June 30, 2011
Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretionLeah J Anderson, Kai Lin, Teresa Compton, et al.
Annals of the New York Academy of Sciences|November 20, 2002
Cholinergic and peptidergic regulation of phenylethanolamine N-methyltransferase gene expressionDona Lee Wong, Leah J Anderson, Tze-Chun Tai
The Journal of Antimicrobial Chemotherapy|October 6, 2019
A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of ageJason Kim, Firdose Lambey Nakwa, Fábio Araujo Motta, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitorsXiaoling Puyang, Danielle L Poulin, Joanna E Mathy, et al.
Virology|November 26, 2009
Multiple cyclophilins involved in different cellular pathways mediate HCV replicationL Alex Gaither, Jason Borawski, Leah J Anderson, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of General Virology|June 19, 2008
EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathwayLeah J Anderson, Richard Longnecker
Blood|September 26, 2008
Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivoLeah J Anderson, Richard Longnecker
Virology|November 6, 2007
An auto-regulatory loop for EBV LMP2A involves activation of NotchLeah J Anderson, Richard Longnecker
Virology Journal|June 30, 2011
Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretionLeah J Anderson, Kai Lin, Teresa Compton, et al.
Annals of the New York Academy of Sciences|November 20, 2002
Cholinergic and peptidergic regulation of phenylethanolamine N-methyltransferase gene expressionDona Lee Wong, Leah J Anderson, Tze-Chun Tai
The Journal of Antimicrobial Chemotherapy|October 6, 2019
A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of ageJason Kim, Firdose Lambey Nakwa, Fábio Araujo Motta, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitorsXiaoling Puyang, Danielle L Poulin, Joanna E Mathy, et al.
Virology|November 26, 2009
Multiple cyclophilins involved in different cellular pathways mediate HCV replicationL Alex Gaither, Jason Borawski, Leah J Anderson, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Pageof 1